Seres Therapeutics, Inc. Defined Contribution Plan, Cost
Seres Therapeutics, Inc. (MCRB) reported Defined Contribution Plan, Cost of $592.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-12
- Seres Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2016-12-31 was $101.00K.
- Seres Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2016-09-30 was $167.00K.
- Seres Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2016-06-30 was $188.00K.
- Seres Therapeutics, Inc. defined contribution plan, cost for fiscal 2025 was $592.00K, a 44.57% decline from fiscal 2024.
- Seres Therapeutics, Inc. defined contribution plan, cost for fiscal 2024 was $1.07M, a 46.68% decline from fiscal 2023.
- Seres Therapeutics, Inc. defined contribution plan, cost for fiscal 2023 was $2.00M, a 4.27% increase from fiscal 2022.
- Seres Therapeutics, Inc. defined contribution plan, cost for fiscal 2022 was $1.92M, a 76.72% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $592.00K 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $1.07M 10-K · filed 2026-03-12 | |||
| 2023-12-31 | $2.00M 10-K · filed 2026-03-12 | |||
| 2022-12-31 | $1.92M 10-K · filed 2025-03-13 | |||
| 2021-12-31 | $1.09M 10-K · filed 2024-03-05 | |||
| 2020-12-31 | $586.00K 10-K · filed 2023-03-07 | |||
| 2019-12-31 | $542.00K 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $604.00K 10-K · filed 2021-03-02 | |||
| 2017-12-31 | $484.00K 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $268.00K derived: sum of 2 quarters · filed 2019-03-06 | $456.00K derived: sum of 3 quarters · filed 2019-03-06 | $457.00K 10-K · filed 2019-03-06 |
| 2016-09-30 | $167.00K 10-Q · filed 2016-11-10 | $355.00K derived: sum of 2 quarters · filed 2016-11-10 | $356.00K 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $188.00K 10-Q · filed 2016-08-11 | $188.00K 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |